Dr. Namandjé N. Bumpus Principal Deputy Commissioner - FDA | Official Website
Dr. Namandjé N. Bumpus Principal Deputy Commissioner - FDA | Official Website
This is an 83.3% decrease from the number of companies inspected in the previous quarter, when six companies received six inspections.
The only company inspected was involved in the Biologics sector.
The company was in line with FDA regulations, and doesn't need to adjust its managing operations or regulatory/administrative actions.
The FDA routinely inspects facilities across the nation to determine if the workplace and their products are compliant with FDA-regulated laws and regulations implemented to improve overall public health. Inspection results are then disclosed publicly.
The FDA is a government agency that is primarily responsible for monitoring the production and distribution of human and animal drugs, biological products, medical supplies and tobacco products for safety quality, according to its website.
Company Name | Area of Business | Inspection Date | Result |
---|---|---|---|
OneBlood, Inc. | Biologics | 11/03/2023 | No Action Indicated (NAI) |